Dovato 50 mg/300 mg SmPC: Uses, Dose, Safety
Quick summary Dovato 50 mg/300 mg film-coated tablets contain dolutegravir and lamivudine. This SmPC summary covers the main approved use, key ingredients, how it is taken, and important safety points for adults and adolescents....
This content is for educational purposes only and does not replace medical advice, diagnosis or treatment from a qualified healthcare professional.
Quick summary
Dovato 50 mg/300 mg film-coated tablets contain dolutegravir and lamivudine. This SmPC summary covers the main approved use, key ingredients, how it is taken, and important safety points for adults and adolescents.
Medical disclaimer: This article is a general summary of product information and is not a substitute for the official SmPC, patient leaflet, or advice from a qualified healthcare professional. Always check the latest official document and speak with a doctor or pharmacist about individual treatment questions.
What Dovato 50 mg/300 mg film-coated tablets are used for
Dovato is used for the treatment of HIV-1 infection in adults and adolescents over 12 years of age who weigh at least 40 kg, where there is no known resistance to integrase inhibitors or lamivudine.
The tablet combines two active substances in one daily medicine, which can simplify treatment. It is part of antiretroviral therapy and is intended to help reduce HIV levels in the body.
Important information from the SmPC
The Summary of Product Characteristics is the official technical document for healthcare professionals. It usually includes information on:
- approved uses
- active ingredients and excipients
- how the medicine is taken
- warnings, precautions, and interactions
- possible side effects
- contraindications and special population guidance
For Dovato, the SmPC is especially important because treatment suitability depends on factors such as resistance history and other medicines a patient may be taking.
What ingredients are in Dovato?
The active ingredients are:
- Dolutegravir 50 mg
- Lamivudine 300 mg
Dolutegravir is an integrase inhibitor, and lamivudine is a nucleoside reverse transcriptase inhibitor. Together, they are used to help control HIV-1 infection.
The tablet also contains other ingredients that support tablet formation and stability. For the full list of excipients, check the official product leaflet or SmPC.
How Dovato is taken
Dovato is taken as one tablet once daily, with or without food.
If a dose is missed, the usual advice is to take it when remembered unless it is nearly time for the next dose. In that case, the missed dose is generally skipped and the regular schedule continued. Do not take two doses at the same time unless a healthcare professional has advised otherwise.
People with kidney or liver problems may need extra medical review before and during treatment. The official SmPC should be checked for the most up-to-date guidance.
Possible side effects
Like all medicines, Dovato can cause side effects. The current content mentions:
- headache
- nausea
- allergic reactions
Any new, severe, or persistent symptoms should be discussed with a healthcare professional. Signs of a serious allergic reaction need urgent medical attention.
Monitoring may be needed during treatment, depending on the person’s medical history and other medicines.
Who should not use Dovato?
Dovato is not suitable for everyone. The current content states that it is contraindicated in people with known hypersensitivity to its components.
It is also not recommended for children under 12 years of age or for those weighing less than 40 kg.
Before treatment is started, a healthcare professional should review the person’s full medical history, including any previous resistance information and all current medicines.
Drug interaction and prescribing checks
The original content notes that some medicines may not be suitable to use alongside Dovato, and fampridine is specifically mentioned as not recommended with this medicine.
Because interaction risks can change depending on the full medicine list, the official SmPC and pharmacist review are important before use.
FDA approval status
The current content states that Dovato received FDA approval in 2019. For the latest regulatory and prescribing information, readers should verify the current official sources in their country.
At a glance
| Topic | Summary |
|---|---|
| Medicine | Dovato 50 mg/300 mg film-coated tablets |
| Active ingredients | Dolutegravir 50 mg and lamivudine 300 mg |
| Main use | Treatment of HIV-1 infection in eligible adults and adolescents |
| How taken | One tablet once daily, with or without food |
| Key checks | Resistance history, age/weight suitability, interactions, and official SmPC guidance |
Frequently asked questions
▸ What is DOVATO 50/300 mg used for?
It is used for the treatment of HIV-1 infection in adults and adolescents over 12 years of age who weigh at least 40 kg and who do not have known resistance to integrase inhibitors or lamivudine.
▸ What is a Summary of Product Characteristics?
An SmPC is the official technical document for a medicine. It gives healthcare professionals information on approved use, dosing, warnings, interactions, side effects, and other prescribing details.
▸ How is Dovato usually taken?
The current content states that it is taken as one tablet once daily, with or without food. The official leaflet or SmPC should be checked for full instructions.
▸ What side effects are mentioned in the content?
Headache, nausea, and allergic reactions are listed. Any concerning or severe symptoms should be reviewed by a healthcare professional.
▸ Who should check the official SmPC before use?
Anyone involved in prescribing, dispensing, or taking the medicine should check the official SmPC, especially if there is a history of resistance, kidney or liver problems, or possible drug interactions.
▸ Is the price the same everywhere?
No. The price can vary by country, pharmacy, and insurance coverage. Local sources should be checked for current pricing information.
Safety reminder: HIV treatment decisions should be made with a qualified healthcare professional. Always use the latest official product information, and seek urgent help for severe reactions, breathing problems, swelling, or other serious symptoms.
Medical disclaimer
This content is for educational purposes only. It should not be used as a substitute for professional medical advice, diagnosis or treatment. Always ask a doctor, pharmacist or qualified healthcare professional before starting, stopping or changing any medicine.
Sources and verification
The following sources or official references are listed to support verification of the medicine information discussed in this article.
Medicine information can change and may vary depending on country, product formulation, patient history and professional guidance. Always check official medicine information and ask a healthcare professional for personal medical questions.